Osstem Implant.

Osstem Implant's English company outline lists OSSTEM IMPLANT CO., LTD., CEO Haesung Kim, incorporation on 8 January 1997, and headquarters at 3 Magokjungang 12-ro, Gangseo-gu, Seoul. Manufacturing headquarters are listed at 66-16 Bansong-ro 513beon-gil, Haeundae-gu, Busan. The outline's figures as of March 2026 are 6,800 domestic and global employees, capital of 5.42 million US dollars, and 2025 sales of 938.5 million US dollars. Those are the company's figures on that page.

The same outline says US FDA certification was acquired in 2002, a German subsidiary opened in Eschborn in 2005, the company was renamed Osstem Implant in 2006, and it listed on KOSDAQ in 2007. It says Hiossen implants were produced and launched in the United States in 2008, and that the TS III SA implant and the CAS kit launched in 2010. The business description covers dental implants and equipment, dental materials, orthodontic materials, software, and clinic interiors.

A Hiossen Canada history page says the US company was incorporated in Pennsylvania in 2006, bought land in Fairless Hills in 2008, and had a manufacturing facility operating in 2009. It also says Osstem products are used in more than 70 countries. Ranking lines on that page, including a claim of being first in Asia Pacific, are Hiossen's marketing. This profile does not repeat them as an independent finding.

TS, KS, SS, and other system names are different implants. The outline ties TS III SA to 2010. A later implant with a similar prefix is not that 2010 product. Surgical kits, abutments, and the fixture have to match the system named in the protocol. The outline also says the company developed Hanaro practice-management software and an implant training center in its early years, acquired FDA clearance in 2002, and opened the Bone Science Research Institute in 2008. Software and a research institute are not the fixture in the tray. Order the implant reference that the surgical plan names. The outline's main businesses also include quasi-drugs and clinic interior work. Those lines can appear on a corporate account and still have nothing to do with the implant lot in the surgery kit.

Osstem suits a surgical practice that wants the Korean implant system, or the Hiossen-labeled US version, and will keep prosthetic parts inside that system. Motors are compared on the implant motor guide.

Grafts placed at the same visit are a different product. See the bone grafting guide.

The outline splits the corporate office in Seoul from manufacturing headquarters in Busan. Hiossen is the US production name dated to 2008. Country of origin on the box is the fact that matters for a purchasing policy.

Software and clinic-interior services are also listed in the business description. They are not the implant. Do not let a practice-management subscription ride on the fixture order unless you meant to buy it.

Match fixture, abutment, and torque values to one system. TS III SA is a 2010 launch on the company outline. Ask the dealer for the current reference code if the quote only says Osstem or Hiossen.

The March 2026 employee and sales figures are the company's. They do not describe a clinical success rate.